- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00079495
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects. The investigational drug will be administered in the clinic weekly for 5 injections (induction phase) then monthly for 8 additional injections (maintenance phase).
Approximately 150 male and female patients (100 active and 50 placebo), aged 18 to 55 years, with relapsing MS and at least one but no more than 10 total Gd-enhancing lesions on cranial MRI scans during the run-in phase will be randomized into this study.
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding
Fase
- Fase 2
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female, 18 to 55 years of age
- Diagnosed with relapsing multiple sclerosis, with at least one relapse in the last two years
- Females must not plan on becoming pregnant
- Females must either be post-menopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control and willing to continue birth control until 30 days after the last dose of study drug
- Males must not intend to impregnate a partner during the study or for 30 days after the study and must also practice acceptable birth control with their partners
Exclusion Criteria:
- Significant long-lasting disease of the immune system other than multiple sclerosis
- Past or current medical disease (heart, liver, kidney, etc.) including severe asthma, cancer or advancing brain or spinal cord disorder
- Known or suspected long-lasting infectious disease including HIV, hepatitis B, or hepatitis C
- Treatment with certain steroid or hormone medications within 30 days before the pre-study MRI scan
- Treatment with other medications that suppress the immune system within 6 months before the pre-study MRI scan
- Certain treatments and medications are not allowed
- Laboratory and other tests will be performed to determine further eligibility
- History of drug or alcohol abuse in the last year
- History of medical or psychiatric condition that could pose a risk for participation in the study
- Females who are pregnant or breast feeding
- Participation in any other trial of an investigational agent within 90 days before the start of the study
- History of not following instructions with past therapy.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NBI-5788-0201
- MS APL
- Neurocrine
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Multipel sclerose
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeKlassisk Hodgkin lymfom | Lymfocytrigt klassisk Hodgkin-lymfom | Ann Arbor Stage IB Hodgkin lymfom | Ann Arbor Stage II Hodgkin lymfom | Ann Arbor Stage IIA Hodgkin lymfom | Ann Arbor Stage IIB Hodgkin lymfom | Ann Arbor Stage I Hodgkin lymfom | Ann Arbor Stage I Mixed Cellularity Klassisk Hodgkin-lymfom og andre forholdForenede Stater
Kliniske forsøg med NBI-5788
-
Ono Pharmaceutical Co. LtdAfsluttet
-
Ono Pharmaceutical Co. LtdAfsluttet
-
Changhai HospitalThe Second Hospital of Hebei Medical University; Air Force Military Medical... og andre samarbejdspartnereRekrutteringKolorektal fastsiddende savtakket læsionKina
-
Midwest Biomedical Research FoundationMedical University of South Carolina; Academisch Medisch Centrum - Universiteit... og andre samarbejdspartnereAfsluttetGastroøsofageal refluks | Barrett EsophagusForenede Stater, Holland
-
Shanghai Jiao Tong University School of MedicineBeijing Friendship Hospital; The Third Xiangya Hospital of Central South... og andre samarbejdspartnereRekrutteringDiminutive kolorektale polypperKina
-
Prince of Songkla UniversityAfsluttetKolorektale neoplasmer | Kolorektal polypThailand
-
Portuguese Oncology Institute, CoimbraAfsluttetKolorektal cancer | Gentagelse, lokal neoplasmaPortugal
-
Shanghai Jiao Tong University School of MedicineAfsluttet
-
The Leeds Teaching Hospitals NHS TrustUkendtColitis ulcerosa (UC)Det Forenede Kongerige
-
Lotung Poh-Ai HospitalAfsluttet